MICROQUIN

Creating Next Generation

Treatments for Cancer

MicroQuin is committed to redefining the therapeutics landscape for patients facing severe diseases

Boston 2018 Finalist

+14M

new cases per year and growing

$100B

per annum spent
on cancer medicines

$800B

per annum spent
on cancer care

OUR CANCER THERAPEUTIC

Despite advances in new cancer drug modalities, treatment regimens still heavily depend on therapies with low specificity and high toxicity to kill cancer cells. Many new drugs can only halt or slow tumor growth but ultimately require combination with chemotherapy, which eradicates healthy cells along the way.

​

MicroQuin has developed first-in-class therapies that manipulate a transmembrane target critical to tumorigenesis and cancer cell survival. The unique interaction of our therapy with this novel and broadly impactful target results in significant efficacy killing cancer cells while leaving healthy cells unscathed.